[go: up one dir, main page]

UY31123A1 - Proteinas de fusion natriureticas - Google Patents

Proteinas de fusion natriureticas

Info

Publication number
UY31123A1
UY31123A1 UY31123A UY31123A UY31123A1 UY 31123 A1 UY31123 A1 UY 31123A1 UY 31123 A UY31123 A UY 31123A UY 31123 A UY31123 A UY 31123A UY 31123 A1 UY31123 A1 UY 31123A1
Authority
UY
Uruguay
Prior art keywords
fusion proteins
natural fusion
disclosed
domains
antibody
Prior art date
Application number
UY31123A
Other languages
English (en)
Inventor
Kevin Mcdonnell
Adam Mezo
Uwe Schoenbeck
Keith Canada
Eugene R Hickey
Original Assignee
Syntonix Pharmaceuticals Inc
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31123(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syntonix Pharmaceuticals Inc, Boehringer Ingelheim Int filed Critical Syntonix Pharmaceuticals Inc
Publication of UY31123A1 publication Critical patent/UY31123A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)

Abstract

Se dan a conocer proteínas de fusion de péptido natriurético que comprenden péptidos natriuréticos unidos a dominios Fc de anticuerpo, moléculas de ácido nucleico que codifican para las proteínas de fusion dadas a conocer en el presente documento, vectores de expresion que expresan dichas proteínas de fusion, composiciones farmacéuticas que comprenden dichas proteínas de fusion y métodos para su uso terapéutico.
UY31123A 2007-06-06 2008-06-05 Proteinas de fusion natriureticas UY31123A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94245507P 2007-06-06 2007-06-06

Publications (1)

Publication Number Publication Date
UY31123A1 true UY31123A1 (es) 2008-11-28

Family

ID=39717543

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31123A UY31123A1 (es) 2007-06-06 2008-06-05 Proteinas de fusion natriureticas

Country Status (10)

Country Link
US (1) US20100310561A1 (es)
EP (1) EP2162464A1 (es)
JP (1) JP2010530222A (es)
AR (1) AR066885A1 (es)
CA (1) CA2689492A1 (es)
CL (1) CL2008001661A1 (es)
PE (1) PE20090311A1 (es)
TW (1) TW200906849A (es)
UY (1) UY31123A1 (es)
WO (1) WO2008154226A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
EP2413969A4 (en) * 2009-03-30 2012-09-05 Boehringer Ingelheim Int FUSION PROTEINS WITH DOG FC ELEMENTS
HRP20161739T1 (hr) 2009-05-20 2017-03-10 Biomarin Pharmaceutical Inc. VARIJANTE NATRIURETIČNOG PEPTIDA C-tipa
TW201120210A (en) * 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
AU2011245005A1 (en) 2010-04-30 2012-11-22 Alexion Pharma Holding Methods, compositions, and kits for the treatment of matrix mineralization disorders
US8921516B2 (en) * 2010-12-08 2014-12-30 Corning Incorporated Synthetic, defined fibronectin mimetic peptides and surfaces modified with the same
CA2823066A1 (en) * 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
CN107261119A (zh) 2011-02-28 2017-10-20 独立行政法人国立循环器病研究中心 恶性肿瘤转移抑制用药物
JP6038795B2 (ja) * 2011-08-19 2016-12-07 国立研究開発法人国立循環器病研究センター ナトリウム利尿ペプチド受容体ｇｃ−ａアゴニスト及びｇｃ−ｂアゴニストを組み合わせてなる悪性腫瘍の増悪防止用医薬
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
TW201442721A (zh) 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd 糖鏈修飾心房利尿鈉肽
LT3116486T (lt) * 2014-03-14 2020-04-10 Biomolecular Holdings Llc Hibridinis imunoglobulinas, turintis nepetidilinę jungtį
TWI593967B (zh) * 2014-05-01 2017-08-01 高雄醫學大學 二級抗體所辨識之抗原決定位及其用途
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
CN104861075B (zh) * 2015-05-08 2018-06-08 成都金凯生物技术有限公司 一种长效重组人脑钠肽融合蛋白及其制备方法与用途
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
WO2018003983A1 (ja) * 2016-07-01 2018-01-04 第一三共株式会社 ｈＡＮＰ－Ｆｃ含有分子コンジュゲート
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
MX2019010960A (es) * 2017-03-22 2020-01-20 Pharmain Corp Agonistas del receptor natriuretico a (npra), composiciones y usos de los mismos.
CA3057502A1 (en) 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
EP3553081A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Atrial natriuretic peptide engrafted antibodies
EP3553079A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft C-type natriuretic peptide engrafted antibodies
EP3553082A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Brain natriuretic peptide engrafted antibodies
JP2021534111A (ja) 2018-08-10 2021-12-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法
MY205168A (en) * 2018-10-23 2024-10-04 Regeneron Pharma Anti-npr1 antibodies and uses thereof
CN110964098B (zh) * 2019-10-23 2022-10-04 武汉奥科博泰生物科技有限公司 一种n端脑钠肽变体蛋白及其制备方法和应用
US12433938B2 (en) 2019-12-09 2025-10-07 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
EP4263616A1 (en) 2020-12-18 2023-10-25 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to npr1 agonists
AU2022218782A1 (en) 2021-02-12 2023-08-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CN120435308A (zh) 2022-10-21 2025-08-05 伊莱利利公司 长效利尿钠肽及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011498A2 (en) * 2002-07-31 2004-02-05 Conjuchem Inc. Long lasting natriuretic peptide derivatives
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
WO2005007809A2 (en) * 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
BRPI0406606A (pt) * 2003-11-13 2005-12-06 Hanmi Pharm Ind Co Ltd Composição farmacêutica compreendendo uma região fc de imunoglobulina como um veìculo
KR100754667B1 (ko) * 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
WO2007047504A2 (en) * 2005-10-14 2007-04-26 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins
US8008257B2 (en) * 2005-10-20 2011-08-30 University Of Ottawa Heart Institute ANF fusion proteins
US20080181903A1 (en) * 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region

Also Published As

Publication number Publication date
JP2010530222A (ja) 2010-09-09
US20100310561A1 (en) 2010-12-09
CA2689492A1 (en) 2008-12-18
CL2008001661A1 (es) 2009-03-20
EP2162464A1 (en) 2010-03-17
PE20090311A1 (es) 2009-04-09
AR066885A1 (es) 2009-09-16
TW200906849A (en) 2009-02-16
WO2008154226A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
UY31123A1 (es) Proteinas de fusion natriureticas
BR112012009854B8 (pt) proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, método de confecção da referida proteína de ligação e uso da mesma
CR11282A (es) Proteinas enlazadas al antigeno de celula de cepa mcdonough de felino humanas
CO6630173A2 (es) Moléculas de unión a seroalbuminae
AR074399A1 (es) Moleculas biespecificas de union a egfr/igfir
CL2011002129A1 (es) Proteinas de union a il-17; construccion de proteina de union a il-17 que comprende un polipeptido ligador o un dominio constante de una inmunoglobulina; conjugado de proteina de union a il-17; vector y celula huesped; composicion para la liberacion de una proteina de union; metodo para reducir la actividad de la il-17.
CO6690759A2 (es) Anticuerpos, fragmentos de unión o derivados de los mismos que se unen específicamente a la proteína 4-1 bb
AR077088A1 (es) Proteinas biespecificas de union a antigeno
UY30324A1 (es) Proteinas de fusion del rage, formulaciones y métodos de uso
BRPI0812400A2 (pt) Unidade, hibridoma, composição farmacêutica, método para identificar uma unidade, anticorpo isolado a uma unidade de ligação de antígeno do mesmo, molécula peptídica, e, uso da unidade.
MX2013015323A (es) Polipeptidos de fusion de serpina y metodos de uso de los mismos.
CL2007002157A1 (es) Proteina de fusion que comprende una exendina-4 fusionada a una transferrina; acido nucleico, vector y celula huesped que codifican dicha proteina; composicion farmaceutica que comprende dicha proteina; y uso de la proteina de fusion para tratar diab
IN2014DN03451A (es)
DOP2014000083A (es) Inmunoenlazadores dirigidos contra el tnf
AR080914A1 (es) Proteinas de union al beta-amiloide
AR080229A1 (es) Proteinas de dominio de armazon de fibronectina que se unen a il -23 (interleucina 23)
EP2352523A4 (en) IMPROVED ANTI-CD19 ANTIBODIES
AR072680A1 (es) Axmi-115 axmi-113 axmi-005 axmi-163 y axmi-184 proteinas insecticidas y metodos de uso de las mismas
MX350962B (es) Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion.
CL2013000019A1 (es) Proteina fijadora de antigeno aislada que fija el factor de crecimiento epidermico fijador de heparina (hg-egf); molecula de acido nucleico que la codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que la comprende; y su uso para tratar una enfermedad hiperproliferativa.
BRPI0811333B8 (pt) proteína de fusão compreendida de taci truncado e de imunoglobulina fc, sequência de dna, vetor, microrganismo transgênico, uso da proteína de fusão, e composição farmacêutica
CL2014000699A1 (es) Proteina de union al antigeno cd27l; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; composicion que la comprende; su uso para tratar cancer, trastornos autoinmunitarios o inflamatorios; y metodo para elaborar un conjugado anticuerpo cd27l-farmaco.
WO2008074867A3 (en) Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use
PE20090225A1 (es) Proteinas de fusion que degradan el peptido beta amiloide
WO2009142460A3 (en) Antibody-peptide fused synergibody

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171117